What barriers and facilitators modify the effectiveness of smoking cessation programs in patients with COPD?
What is the comparative effectiveness and cost effectiveness of counseling plus nicotine replacement vs. counseling plus bupropion vs. counseling plus varenicline on smoking cessation rates, patient-reported outcomes (symptom frequency, activities of daily living, quality of life, sleep quality, exacerbations), and COPD and non-COPD morbidity/mortality?
How can we reduce the burden of vascular disease by promoting healthy lifestyle including diet, exercise, and smoking cessation?
We are concerned about access to smoking cessation programs in populations that are hard to reach (rural) and who have other challenges (underserved/marginalized populations including people with serious mental illness). What kind of computer-based or mobile health technologies can assist these groups?
What is nicotine addiction in the absence of other materials? What cues are associated with smoking? We would like to see brain reward studies in special populations. We are also interested in understanding possible reduced harm in people who use e-cigarettes in cessation attempts, and understanding whether e-cigs are a gateway to other risky behaviors for young people who are experimenting.
There should be research on how best to educate medical students, residents, and fellows on strategies for effectively helping patients quit using tobacco products.